Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2841-2849

  Lee, Dong Yun ^a   Park, Kyeongsoon ^b   Kim, Sang Kyoon ^a   Park, Rang Woon ^d   Kwon, Ick Chan ^b   Kim, Sang Yoon ^c   Byun, Youngro ^a,e  

^a Seoul National University   (South Korea)

^b University of Ulsan   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Kyungpook National University School of Medicine   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCHOLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; LOW MOLECULAR WEIGHT HEPARIN DEOXYCHOLIC ACID; NADROPARIN; PADGEM PROTEIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; LMWH DOCA CONJUGATE; LMWH-DOCA CONJUGATE;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CELL ACTIVATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LUNG CARCINOMA; LUNG METASTASIS; MALE; MELANOMA CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; EXPERIMENTAL MELANOMA; LUNG TUMOR; METABOLISM; METASTASIS; ORAL DRUG ADMINISTRATION; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE, TUMOR; DEOXYCHOLIC ACID; DISEASE MODELS, ANIMAL; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; P-SELECTIN;

EID: 52049121633     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0641     Document Type: Article

References (34)

1. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
2. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001;53: 93-105.
3. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revised: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA2001;98:3352-7.
4. Nelson RM, Cecconi 0, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;82:3253-8.
5. Koengin A, Norgard-Sumnicht K, Linhardt R,Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998;101:877-89.
6. Ludwig RJ, Boehme B, Podda M, et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004;64: 2743-50.
7. Casu B. Structure of heparin and heparin fragments. Ann N Y Acad Sci 1989;556.i -17.
8. HirshJ. Heparin. N Engl J Med 1991;324:1565-79.
9. Lee AY. Cancer and thromboembolic disease: pathogenic mechanisms. CancerTreat Rev 2002;28:137-40.
10. Jaques LB. Heparins: anionic polyelectrolyte drugs. Pharmacol Rev1980;31:100-66.
11. Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 1998;34:135-54.
12. Caramazza I, DAtri G, Bossi ML, De Ponti F, DAngelo L, Crema A. Intraduodenal absorption of the new FU-heparin salt ITF 1057 in the conscious dog.Thromb Res 1991;62:785-9.
13. Baughman RA, Kappor SC, Agarwal RK, Kisicki J, Catella-Lawson F, FitzGerald GA. Oral delivery of anticoagulant doses of heparin. A randomized. double-blind, controlled study in humans. Circulation 1998;98:1610-5.
14. Leone-Bay A, Paton DR, Weidner JJ. The development of delivery agents that facilitate the oral absorption of macromolecular drugs. Med Res Rev2000;20: 169-86.
15. Salartash K, Lepore M, Gonze MD, et al. Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Ann Surg 2000;231:789-94.
16. Lee YK, Nam JH, Shin HC, ByunY. Conjugation of low-molecular-weight- heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation 2001;104:3116-20.
17. Lee YK, Kim SK, Lee DY, et al. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J Control Release 2006;111:290-8.
18. Kim SK, Kim K, Lee S, et al. Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface plasmon resonance. J Pharm Biomed Anal 2005:39:861 -70.
19. Kim SK.Vaishali B, Lee E, et al. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb Res 2006;117: 419-27.
20. Lee DY, Kim SK, Kim YS, et al. Suppression of angio- genesis and tumor growth by orally active deoxycholic acid-heparin conjugate. J Control Release 2007;118: 310-7.
21. Park K, Lee GY, KimYS, et al. Heparin-deoxycholic acid chemical conjugates as an anticancer drug carrier and its antitumor activity. J Control Release 2006;114: 300-6.
22. Park K, Lee SK, Son DH, et al. The attenuation of experimental lung metastasis by a bile acid acylated- heparin derivative. Biomaterials 2007;28:2667-76.
23. Park K, KimYS, Lee GY, etal. Antiangiogenic effect of bile acid acylated heparin derivative. Pharm Res 2007;24:176-85.
24. Park K, Lee GY, Park RW, et al. Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma. Pharm Res 2008;25:268-76.
25. Wei M.Tai G, GaoY, et al. Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J Biol Chem 2004;279:29202-10.
26. Luscinskas FW, Ding H, Lichtman AH. P-selectin and vascular cell adhesion molecule 1 mediate rolling and arrest, respectively, of CD4+ T lymphocytes on tumor necrosis factor ct-activated vascular endothelium under flow. J Exp Med 1995;181:1179-86.
27. Mannori G, Crottet P, Cecconi 0, et al. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res 1995; 55:4425-31.
28. KimYJ, Borsig L, Varki NM,Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A 1998:95:9325-30.
29. Kramer RH, McDonald KA, Crowley E, Ramos DM, Damsky CH. Melanoma cell adhesion to basement membrane mediated by integrin-related complexes. Cancer Res 1989;49:393-402.
30. Greets HW, Jay RM, Code Kl, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701 -7.
31. Rutherford EJ, SchoolerWG, Sredzienski E, Abrams JE, Skeete DA. Optimal dose of enoxaparin in critically ill trauma and surgical patients. J Trauma 2005;58: 1167-70.
32. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-0- sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002;110:127-36.
33. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A 2002;99:2193-8.
34. Hirsh J, Raschke R. Heparin and low-molecular- weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188-203S.